To amend the Public Health Service Act to provide that clinical studies required for licensure of biological products as biosimilar shall not be required to include the assessment of immunogenicity, pharmacodynamics, or comparative clinical efficacy.
119th Congress
Introduced Apr 10, 2025
Sponsors
Legislative Progress
Introduced
Introduced
Committee
Passed
Apr 10, 2025
Mr. Paul introduced the following bill; which was read twice …
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology